{
  "paper_id": "PMC10425685",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425685/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Hematologic malignancy NGS panel design. (A) Bar chart showing the number of NGS panels offered for hematologic malignancies by responding laboratories, including a single comprehensive cancer panel, a single comprehensive HMP, and 2 or more panels. (B) Bar chart showing the number of genes offered ranging from small panels with 21 to 50 genes to large panels with more than 300 genes. The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425685/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/b64bd9df2516/BLOODA_ADV-2023-010149-gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "NGS panel characteristics. Bar chart showing the LOD of variant allele frequency reported for NGS panels.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425685/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/40d09d41aa49/BLOODA_ADV-2023-010149-gr2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Laboratory operations. (A) Bar chart showing the average number of hematologic malignancy NGS panels run per month by responding institutions ranging from <10 cases to 401 to 600 cases per month. (B) Bar chart showing average TAT for acute cases ranging from 2 to 7 calendar days to 15 to 21 calendar days. (C) Bar chart showing different approaches for achieving rapid turnaround times for acute cases. Some institutions reported >1 approach. (D) Bar chart showing ancillary testing methods used to cover NGS limitations. Some institutions reported >1 method.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425685/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68f3/10425685/89a78c8007ed/BLOODA_ADV-2023-010149-gr3.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Survey results were separately analyzed for (1) all panels (GOAL panels in use as primary tests or in development or other panels for institutions without a GOAL panel) and (2) specifically for GOAL panels in use or development.Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Laboratories using UMIs, therefore, reported lower mean consensus coverage for appropriate technical reasons.Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A more even distribution was seen for GOAL panels regarding hg19 (6 of 10 [60.0%]) vs hg38 (4 of 10 [40.0%]) use.Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Hematologic malignancy NGS panel design\nMost laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes offered are further stratified into 3 categories based on the number of NGS panels offered: respondents with single comprehensive cancer panel, respondents with single comprehensive HMP, and combined group of respondents with >1 panel. (C) Bar chart generally showing excellent coverage of myeloid processes with no more than 5 genes needed to be added for most NGS panels. (D) Bar chart showing more moderate coverage of lymphoid processes with wider range of number of genes needed.The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most laboratories were or will be testing hematologic malignancies with either a single hematologic malignancy panel (HMP) focused on combined myeloid/lymphoid malignancies (7 of 18 [38.9%]) or a single comprehensive cancer panel testing all cancer types (5 of 18 [27.8%]; Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The number of genes included in the panels varied widely from >300 genes (4 of 18 [22.2%]) down to 21 to 50 genes (2 of 18 [11.1%]; Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The vast majority were satisfied with their panels, with 15 of 18 laboratories (83.3%) having no more than 5 genes on their wish list (Figure 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fewer laboratories reported excellent gene panels appropriate for lymphomas (7 of 17 [41.2%]), with more laboratories reporting good (7 of 17 [41.2%]) and poor (3 of 17 [17.6%]) selection of lymphoid-related genes (Figure 1D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel D",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assay characteristics\nThe limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The limit of detection (LOD) among all participant assays ranged from 2% to 10%, with most (12 of 13 [92.3%]) at 5% or lower (Figure 2) for single nucleotide variants.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Operations\nOverall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Some institutions reported >1 method.Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall laboratory testing volume varied from <10 cases to 401 to 600 cases per month (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Most reported shorter average TATs for acute cases (eg, acute myeloid leukemia) ranging from 2 to 7 (5 of 15 [33.3%]) and from 8 to 14 (8 of 15 [53.3%]) calendar days, whereas a few reported 15 to 21 (2 of 15 [13.3%]) calendar days (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Approaches for dealing with rapid TAT requirements for acute cases included separate single gene assays for rapid TAT (see “Hematologic malignancy NGS development plans”) with routine NGS panels (7 of 15 [46.7%]), regular panels with rapid TAT/prioritized testing (6 of 15 [40.0%]), and separate small panels for rapid TAT (3 of 15 [20.0%]) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Many laboratories reported using ancillary testing to cover NGS limitations, including FLT3-ITD via capillary electrophoresis (CE; 9 of 15 [60.0%]), CALR via CE (2 of 15 [13.3%]), single gene CEBPA (3 of 15 [20.0%]), and single gene IDH1/IDH2 (4 of 15 [26.7%]) testing (Figure 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 99,
    "images_downloaded": 3,
    "tables_filtered": 61
  }
}